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exportin-1 (XPO-1) inhibitor, shows
antitumor effects modulating the
expression of cyclin D1 and survivin in
prostate cancer models
Giovanni Luca Gravina1, Andrea Mancini1, Patrizia Sanita1, Flora Vitale1, Francesco Marampon1, Luca Ventura2,
Yosef Landesman3, Dilara McCauley3, Michael Kauffman3, Sharon Shacham3 and Claudio Festuccia1*Unfortunately, the original version of this article [1]
contained a mistake. The word ‘survivin’ in the title was
incorrectly included as ‘surviving’. The title has been
corrected above and in the original article.
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